Guggenheim initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $45 price target The firm has a positive view of NBD1 stabilization as a therapeutic opportunity for cystic fibrosis patients. Preclinical evidence suggests Sionn’s lead candidates, SION-719 and SION-451, have the potential to restore CFTR maturation and function when they’re co-administered with the company’s complementary CFTR modulators, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics: Promising NBD1 Stabilizers Poised to Challenge Vertex in the $11 Billion CF Market
- Sionna Therapeutics: Innovative NBD1 Stabilizers and Strategic Synergies Drive Buy Rating
- Opening Day: AI mobility provider, steel veteran make trading debuts
Questions or Comments about the article? Write to editor@tipranks.com